Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Xenazine tetrabenazine: Additional Phase III data

According to FDA briefing documents, data from the double-blind, U.S. Phase III TBZ 103, 004 trial (Study 004) in 84 patients showed a lack of benefit of Xenazine

Read the full 281 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE